Barclays
AVBP icon

Barclays’s ArriVent BioPharma AVBP Stock Holding History

Barclays’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.47M Buy
70,970
+5,562
+9% +$164K ﹤0.01% 2230
2026
Q1 		$1.51M Sell
65,408
-63,765
-49% -$1.44M ﹤0.01% 2523
2025
Q4 		$2.6M Sell
129,173
-762
-0.6% -$15.9K ﹤0.01% 2740
2025
Q3 		$2.4M Buy
129,935
+12,723
+11% +$250K ﹤0.01% 2759
2025
Q2 		$2.55M Buy
117,212
+76,629
+189% +$1.59M ﹤0.01% 2666
2025
Q1 		$750K Sell
40,583
-12,916
-24% -$316K ﹤0.01% 3279
2024
Q4 		$1.43M Buy
53,499
+11,977
+29% +$344K ﹤0.01% 3141
2024
Q3 		$976K Buy
41,522
+38,132
+1,125% +$866K ﹤0.01% 3377
2024
Q2 		$62.9K Sell
3,390
-10,818
-76% -$193K ﹤0.01% 4117
2024
Q1 		$254K Buy
+14,208
New +$287K ﹤0.01% 3985

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Barclays's AVBP Position: Q2 2026 in Review

Barclays increased its ArriVent BioPharma (AVBP) stake by 8.5% in Q2 2026, buying an estimated $164K and bringing the position to 70,970 shares worth $2.47M. The position accounts for ﹤0.01% of the portfolio, ranked #2230.

Barclays first reported a position in AVBP in Q1 2024 and has held it in 10 quarters since. The position peaked at $2.6M in Q4 2025. 157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Barclays held 70,970 shares of ArriVent BioPharma worth $2.47M as of Q2 2026.
  • Barclays bought 5,562 ArriVent BioPharma shares in Q2 2026, an estimated $164K.
  • ArriVent BioPharma made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2230 holding.
  • Barclays first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 10 quarters since.
  • Barclays's ArriVent BioPharma position peaked at $2.6M in Q4 2025.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.